{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:28:14Z","timestamp":1761870494930,"version":"build-2065373602"},"reference-count":137,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,2,1]],"date-time":"2010-02-01T00:00:00Z","timestamp":1264982400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.3816\/clml.2010.n.003","type":"journal-article","created":{"date-parts":[[2010,2,8]],"date-time":"2010-02-08T21:01:27Z","timestamp":1265662887000},"page":"28-43","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["The Current Status and Future of Multiple Myeloma in the Clinic"],"prefix":"10.3816","volume":"10","author":[{"given":"Sundar","family":"Jagannath","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Palumbo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia","family":"Cunningham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Berenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.3816\/CLML.2010.n.003_bib1","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.blre.2009.07.004","article-title":"The incidental monoclonal protein: Current approach to management of monoclonal gammopathy of undetermined significance (MGUS)","volume":"23","author":"Madan","year":"2009","journal-title":"Blood Rev"},{"key":"10.3816\/CLML.2010.n.003_bib2","doi-asserted-by":"crossref","first-page":"79a","DOI":"10.1182\/blood.V110.11.246.246","article-title":"Monoclonal gammopathy of undetermined significance: estimated incidence and duration prior to recognition","volume":"110","author":"Kyle","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib3","unstructured":"Kyle R. MGUS\/asymptomatic myeloma\/solitary plasmacytoma: where are we moving in 2009. Paper presented at: Clinical Lymphoma & Myeloma panel: focus on myeloma; May 28, 2009; Orlando, FL."},{"key":"10.3816\/CLML.2010.n.003_bib4","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/j.1365-2141.2006.06235.x","article-title":"Monoclonal gammopathy of undetermined significance","volume":"134","author":"Kyle","year":"2006","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.4065\/84.8.685","article-title":"Disease associations with monoclonal gammopathy of undetermined significance: a population-based study of 17,398 patients","volume":"84","author":"Bida","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.003_bib6","doi-asserted-by":"crossref","first-page":"5370","DOI":"10.1182\/blood-2009-03-207241","article-title":"Are all myelomas preceded by MGUS?","volume":"113","author":"Blade","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib7","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.003_bib8","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.ejim.2009.01.001","article-title":"Systemic manifestations of monoclonal gammopathy","volume":"20","author":"Decaux","year":"2009","journal-title":"Eur J Intern Med"},{"key":"10.3816\/CLML.2010.n.003_bib9","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1365-2141.2007.06936.x","article-title":"Perspectives in treatment of AL amyloidosis","volume":"140","author":"Wechalekar","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib10","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1097\/WCO.0b013e32832fd563","article-title":"Monoclonal gammopathy and neuropathy","volume":"22","author":"Ramchandren","year":"2009","journal-title":"Curr Opin Neurol"},{"key":"10.3816\/CLML.2010.n.003_bib11","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2005.n.011","article-title":"Prognostic factors and predictors of outcome of immunoglobulin M monoclonal gammopathy of undetermined significance","volume":"5","author":"Kyle","year":"2005","journal-title":"Clin Lymphoma"},{"key":"10.3816\/CLML.2010.n.003_bib13","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1182\/blood.V100.4.1417.h81602001417_1417_1424","article-title":"Genomic abnormalities in monoclonal gammopathy of undetermined significance","volume":"100","author":"Fonseca","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib14","doi-asserted-by":"crossref","first-page":"6026","DOI":"10.1158\/1078-0432.CCR-07-0031","article-title":"Hyperdiploidy is a common finding in monoclonal gammopathy of undetermined significance and monosomy 13 is restricted to these hyperdiploid patients","volume":"13","author":"Brousseau","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib15","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1182\/blood-2006-02-005496","article-title":"Integration of global SNP-based mapping and expression arrays reveals key regions, mechanisms, and genes important in the pathogenesis of multiple myeloma","volume":"108","author":"Walker","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0165-4608(01)00511-8","article-title":"Contribution of cytogenetics and in situ hybridization to the study of monoclonal gammopathies of undetermined significance","volume":"132","author":"Lloveras","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.3816\/CLML.2010.n.003_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3816\/CLM.2009.n.061","article-title":"Monoclonal gammopathy of undetermined significance: why identification of these patients and assessment of their skeletons is important","volume":"9","author":"Berenson","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib18","doi-asserted-by":"crossref","first-page":"6289","DOI":"10.1158\/1078-0432.CCR-08-0666","article-title":"Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss","volume":"14","author":"Berenson","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib19","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/CCO.0b013e328331c794","article-title":"Bisphosphonates in breast cancer: teaching an old dog new tricks","volume":"21","author":"Winter","year":"2009","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib20","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1200\/JCO.1998.16.2.593","article-title":"Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group","volume":"16","author":"Berenson","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib21","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1200\/JCO.2007.12.1269","article-title":"American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma","volume":"25","author":"Kyle","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib22","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/annonc\/mdn796","article-title":"The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network","volume":"20","author":"Terpos","year":"2009","journal-title":"Ann Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib23","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMoa070389","article-title":"Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma","volume":"356","author":"Kyle","year":"2007","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.003_bib24","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/S0140-6736(09)60221-X","article-title":"Multiple myeloma","volume":"374","author":"Raab","year":"2009","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.003_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood.V114.22.614.614","article-title":"Multicenter, randomized, open-label, phase III trial of lenalidomide-dexamethasone (len\/dex) vs therapeutic abstention in smoldering multiple myeloma at high risk of progression to symptomatic MM: results of the first interim analysis","volume":"114","author":"Mateos","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib26","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1046\/j.1365-2141.2003.04355.x","article-title":"Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group","volume":"121","year":"2003","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib27","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/leu.2009.89","article-title":"International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib29","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood-2006-04-015784","article-title":"Immunoglobulin free light chains and solitary plasmacytoma of bone","volume":"108","author":"Dingli","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1182\/asheducation-2005.1.373","article-title":"Solitary bone and extramedullary plasmacytoma","author":"Weber","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.003_bib31","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib32","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation-2008.1.306","article-title":"Induction therapy in multiple myeloma","author":"Harousseau","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.003_bib33","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1182\/blood-2009-04-205013","article-title":"Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide, lenalidomide or bortezomib- containing regimens","volume":"114","author":"Kumar","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib34","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1038\/leu.2009.127","article-title":"International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)","volume":"23","author":"Giralt","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib35","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","article-title":"The role of complete response in multiple myeloma","volume":"114","author":"Harousseau","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib36","first-page":"65","article-title":"Superior complete response rate and progression-free survival after autologous transplantation with up-front velcade-thalidomide- dexamethasone compared with thalidomide-dexamethasone in newly diagnosed multiple myeloma","volume":"112","author":"Cavo","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib37","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood.V112.11.2778.2778","article-title":"Superior outcomes associated with complete response: analysis of the phase III VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone","volume":"112","author":"Harousseau","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib38","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","author":"Rajkumar","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib39","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","article-title":"Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib40","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib41","doi-asserted-by":"crossref","first-page":"7073","DOI":"10.1158\/1078-0432.CCR-07-0527","article-title":"Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling","volume":"13","author":"Haessler","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib42","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/sj.bmt.1701062","article-title":"Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Trasplante Hematopoyetico-GETH) and PETHEMA","volume":"21","author":"Alegre","year":"1998","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLML.2010.n.003_bib43","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/sj.bmt.1703717","article-title":"Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma","volume":"30","author":"Singhal","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLML.2010.n.003_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/sj.bmt.1704545","article-title":"High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy","volume":"34","author":"Kumar","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.3816\/CLML.2010.n.003_bib45","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/jnci\/djn439","article-title":"Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Kumar","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.003_bib46","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/CCO.0b013e3283136984","article-title":"Advances in therapy of multiple myeloma","volume":"20","author":"Blade","year":"2008","journal-title":"Curr Opin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib47","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1093\/jnci\/djp126","article-title":"Re: Tandem vs single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis","volume":"101","author":"Giralt","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLML.2010.n.003_bib48","doi-asserted-by":"crossref","unstructured":"Harousseau J, Mathiot C, Attal M, et al. Bortezomib\/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005\/01 trial. Paper presented at: the 2008 meeting of the American Society of Hematology; December 7, 2008; San Francisco, CA.","DOI":"10.1200\/jco.2008.26.15_suppl.8505"},{"key":"10.3816\/CLML.2010.n.003_bib49","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1182\/blood-2008-07-169565","article-title":"Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma","volume":"113","author":"Ludwig","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib50","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0140-6736(07)61537-2","article-title":"Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial","volume":"370","author":"Facon","year":"2007","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.003_bib51","doi-asserted-by":"crossref","first-page":"32a","DOI":"10.1182\/blood.V110.11.78.78","article-title":"Melphalan-prednisone-thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial","volume":"110","author":"Waage","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib52","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1182\/blood.V112.11.162.162","article-title":"Ninety percent sustained complete response (cr) rate projected 4 years after onset of CR in gene expression profiling (GEP)-defined low-risk multiple myeloma (MM) treated with total therapy 3 (TT3): basis for GEP-risk-adapted TT4 and TT5","volume":"112","author":"Barlogie","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib53","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2141.2009.07864.x","article-title":"TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3","volume":"147","author":"Shaughnessy","year":"2009","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib56","first-page":"242","article-title":"Updated follow-up and results of subsequent therapy in the phase III VISTA trial: bortezomib plus melphalan-prednisone versus melphalan-prednisone in newly diagnosed multiple myeloma","volume":"112","author":"San Miguel","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib57","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1182\/blood-2009-01-202010","article-title":"Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone","volume":"114","author":"Kapoor","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib58","first-page":"1262","article-title":"Impact of chromosomal abnormalities del(13), t(4;14), and del(17p) and prior treatment on outcomes in patients with relapsed or refractory multiple myeloma treated with lenalidomide","volume":"112","author":"Avet-Loiseau","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib59","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/blood-2008-12-193458","article-title":"Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13","volume":"114","author":"Reece","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib60","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood-2009-04-217281","article-title":"Risky business in myeloma","volume":"114","author":"Lonial","year":"2009","journal-title":"Blood"},{"issue":"suppl 4","key":"10.3816\/CLML.2010.n.003_bib61","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.3816\/CLM.2008.s.011","article-title":"Treatment of myeloma patients with comorbid conditions: considerations for the clinician","volume":"8","author":"Jagannath","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib62","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1177\/0091270007309563","article-title":"Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis","volume":"47","author":"Chen","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.3816\/CLML.2010.n.003_bib63","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/sj.leu.2405087","article-title":"Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study","volume":"22","author":"San-Miguel","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib64","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/ki.2008.138","article-title":"Approach to acute renal failure in biopsy proven myeloma cast nephropathy: is there still a role for plasmapheresis?","volume":"74","author":"Pillon","year":"2008","journal-title":"Kidney Int"},{"key":"10.3816\/CLML.2010.n.003_bib65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1745-6215-9-55","article-title":"European trial of free light chain removal by extended haemodialysis in cast nephropathy (EuLITE): a randomised control trial","volume":"9","author":"Hutchison","year":"2008","journal-title":"Trials"},{"key":"10.3816\/CLML.2010.n.003_bib66","first-page":"230","article-title":"Lenalidomide: new drug. Myeloma: many questions remain unanswered","volume":"17","year":"2008","journal-title":"Prescrire Int"},{"key":"10.3816\/CLML.2010.n.003_bib67","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib68","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1038\/nrclinonc.2009.128","article-title":"Neurological adverse effects caused by cytotoxic and targeted therapies","volume":"6","author":"Schiff","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib69","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.2008.07573.x","article-title":"Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple myeloma: impact of a dose-modification guideline","volume":"144","author":"Richardson","year":"2009","journal-title":"Br J Haematol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib70","first-page":"437s","article-title":"A phase III study of VMPT versus VMP in newly diagnosed elderly myeloma patients","volume":"27","author":"Palumbo","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib71","doi-asserted-by":"crossref","unstructured":"Richardson P, Lonial S, Jakubowiak A, et al. Lenalidomide, bortezomib and dexamethasone has notable activity in the frontline treatment of myeloma, including patients with high risk disease. Paper presented at: the XIIth International Myeloma Workshop; February 26-March 1, 2009; Washington, DC.","DOI":"10.1016\/S1557-9190(11)70510-8"},{"key":"10.3816\/CLML.2010.n.003_bib72","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib73","doi-asserted-by":"crossref","DOI":"10.1038\/leu.2009.179","article-title":"The use of novel agents in the treatment of relapsed and refractory multiple myeloma","author":"Laubach","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib74","doi-asserted-by":"crossref","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","article-title":"A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies","volume":"15","author":"O\u2019Connor","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1053\/j.seminhematol.2007.02.004","article-title":"Epidemiology and risk factors for venous thrombosis","volume":"44","author":"Cushman","year":"2007","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.003_bib76","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1182\/blood.V99.9.3163","article-title":"Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients","volume":"99","author":"Berenson","year":"2002","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib77","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4065\/82.10.1179","article-title":"Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma","volume":"82","author":"Lacy","year":"2007","journal-title":"Mayo Clin Proc"},{"key":"10.3816\/CLML.2010.n.003_bib79","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib80","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2008.18.8573","article-title":"Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib81","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/nrclinonc.2009.131","article-title":"Hematology: thalidomide maintenance in multiple myeloma","volume":"6","author":"Laubach","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib82","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1182\/blood.V112.11.159.159","article-title":"Bortezomib-doxorubicin-dexamethasone as induction prior to reduced intensity autologous transplantation followed by lenalidomide as consolidation\/maintenance in elderly untreated myeloma patients","volume":"112","author":"Palumbo","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib83","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/leu.2009.147","article-title":"Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"23","author":"Dimopoulos","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib84","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib85","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib86","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2141.2009.07875.x","article-title":"Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed\/refractory multiple myeloma","volume":"147","author":"Vogl","year":"2009","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib88","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/ajh.21517","article-title":"Retreatment with bortezomib alone or in combination for patients with multiple myeloma following an initial response to bortezomib","volume":"84","author":"Sood","year":"2009","journal-title":"Am J Hematol"},{"key":"10.3816\/CLML.2010.n.003_bib89","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3816\/CLM.2008.n.016","article-title":"An observational, retrospective analysis of retreatment with bortezomib for multiple myeloma","volume":"8","author":"Conner","year":"2008","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib90","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/j.1365-2141.2008.07303.x","article-title":"The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma","volume":"143","author":"Niesvizky","year":"2008","journal-title":"Br J Haematol"},{"key":"10.3816\/CLML.2010.n.003_bib91","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1182\/blood.V112.11.3690.3690","article-title":"Efficacy and safety of re-treatment with bortezomib (Velcade(C)) in patients with multiple myeloma: results from a prospective international phase II trial","volume":"112","author":"Petrucci","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib92","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1182\/blood.V112.11.651.651","article-title":"Bortezomib (Velcade)-melphalan-prednisone (VMP) versus Velcade-thalidomide-prednisone (VTP) in elderly untreated multiple myeloma patients: which is the best partner for Velcade: an alkylating or an immunomodulator agent?","volume":"112","author":"Mateos","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib93","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/00000421-200110000-00013","article-title":"Molecular pathways that modify tumor radiation response","volume":"24","author":"Pervan","year":"2001","journal-title":"Am J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib94","unstructured":"Berenson J. Managing complications of myeloma and treatment toxicities. Paper presented at: Clincial Lymphoma & Myeloma panel: focus on myeloma. May 28, 2009; Orlando, FL."},{"key":"10.3816\/CLML.2010.n.003_bib97","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1634\/theoncologist.2009-0003","article-title":"Myeloma bone disease: recent advances in biology, diagnosis, and treatment","volume":"14","author":"Sezer","year":"2009","journal-title":"Oncologist"},{"key":"10.3816\/CLML.2010.n.003_bib98","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1182\/asheducation-2008.1.313","article-title":"Skeletal imaging and management of bone disease","author":"Roodman","year":"2008","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.3816\/CLML.2010.n.003_bib100","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1002\/cncr.11701","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen","year":"2003","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.003_bib101","doi-asserted-by":"crossref","first-page":"5356","DOI":"10.1200\/JCO.2009.21.9584","article-title":"Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the Jaw","volume":"27","author":"Vahtsevanos","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib102","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.3816\/CLML.2010.n.003_bib103","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/j.1445-5994.2008.01824.x","article-title":"Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment","volume":"39","author":"Dickinson","year":"2009","journal-title":"Intern Med J"},{"key":"10.3816\/CLML.2010.n.003_bib104","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib105","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/S0140-6736(09)60010-6","article-title":"Efficacy and safety of balloon kyphoplasty compared with non-surgical care for vertebral compression fracture (FREE): a randomised controlled trial","volume":"373","author":"Wardlaw","year":"2009","journal-title":"Lancet"},{"key":"10.3816\/CLML.2010.n.003_bib106","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1097\/BRS.0b013e3181a3c742","article-title":"Percutaneous treatment of vertebral compression fractures: a meta-analysis of complications","volume":"34","author":"Lee","year":"2009","journal-title":"Spine (Phila Pa 1976)"},{"key":"10.3816\/CLML.2010.n.003_bib107","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa0900563","article-title":"A randomized trial of vertebroplasty for osteoporotic spinal fractures","volume":"361","author":"Kallmes","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.003_bib108","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","article-title":"A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures","volume":"361","author":"Buchbinder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.3816\/CLML.2010.n.003_bib109","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib110","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1309\/AJCPR2M4EUYNHLGM","article-title":"Are renal reference intervals required when screening for plasma cell disorders with serum free light chains and serum protein electrophoresis?","volume":"131","author":"Abadie","year":"2009","journal-title":"Am J Clin Pathol"},{"issue":"suppl 2","key":"10.3816\/CLML.2010.n.003_bib111","first-page":"S255","article-title":"Treatment of diabetic neuropathy and neuropathic pain: how far have we come?","volume":"31","author":"Ziegler","year":"2008","journal-title":"Diabetes Care"},{"key":"10.3816\/CLML.2010.n.003_bib112","doi-asserted-by":"crossref","unstructured":"Steinberg J, Shen J, Sanchez E, et al. Alpha lipoic acid (ALA) inhibits the anti-myeloma effects of bortezomib. Paper presented at: the 2009 annual meeting of the American Society of Hematology; December 5-8; 2009; New Orleans, LA. Abstract 3832.","DOI":"10.1182\/blood.V114.22.3832.3832"},{"key":"10.3816\/CLML.2010.n.003_bib113","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/CAD.0b013e3282f24031","article-title":"Antioxidants block proteasome inhibitor function in endometrial carcinoma cells","volume":"19","author":"Llobet","year":"2008","journal-title":"Anticancer Drugs"},{"key":"10.3816\/CLML.2010.n.003_bib114","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/leu.2009.83","article-title":"Ascorbic acid inhibits antitumor activity of bortezomib in vivo","volume":"23","author":"Perrone","year":"2009","journal-title":"Leukemia"},{"key":"10.3816\/CLML.2010.n.003_bib115","doi-asserted-by":"crossref","first-page":"5927","DOI":"10.1182\/blood-2008-07-171389","article-title":"Green tea polyphenols block the anticancer effects of bortezomib and other boronic acid-based proteasome inhibitors","volume":"113","author":"Golden","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib116","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00280-008-0876-6","article-title":"Central and peripheral nervous system toxicity of common chemotherapeutic agents","volume":"63","author":"Sioka","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLML.2010.n.003_bib117","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1182\/blood-2007-10-117457","article-title":"Thalidomide for treatment of multiple myeloma: 10 years later","volume":"111","author":"Palumbo","year":"2008","journal-title":"Blood"},{"author":"Morgan","key":"10.3816\/CLML.2010.n.003_bib118"},{"key":"10.3816\/CLML.2010.n.003_bib119","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3816\/CLM.2009.n.063","article-title":"Arterial thrombosis with immunomodulatory derivatives in the treatment of multiple myeloma: a single-center case series and review of the literature","volume":"9","author":"Martin","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib120","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/j.beha.2007.10.001","article-title":"Supportive care in multiple myeloma","volume":"20","author":"Ludwig","year":"2007","journal-title":"Best Practice & Research Clinical Haematology"},{"key":"10.3816\/CLML.2010.n.003_bib121","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1053\/j.seminhematol.2009.03.006","article-title":"Infections in patients with multiple myeloma","volume":"46","author":"Nucci","year":"2009","journal-title":"Semin Hematol"},{"key":"10.3816\/CLML.2010.n.003_bib122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/cncr.24006","article-title":"Acyclovir to prevent reactivation of varicella zoster virus (herpes zoster) in multiple myeloma patients receiving bortezomib therapy","volume":"115","author":"Vickrey","year":"2009","journal-title":"Cancer"},{"key":"10.3816\/CLML.2010.n.003_bib124","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S1470-2045(08)70304-8","article-title":"New drugs in multiple myeloma: mechanisms of action and phase I\/II clinical findings","volume":"9","author":"Ocio","year":"2008","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib125","first-page":"435s","article-title":"Final results of PX-171-003-A0, part 1 of an open-label, single-arm, phase II study of carfilzomib (CFZ) in patients (pts) with relapsed and refractory multiple myeloma (MM)","volume":"27","author":"Jagannath","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib126","first-page":"443s","article-title":"PX-171-004, a multicenter phase II study of carfilzomib (CFZ) in patients with relapsed myeloma: An efficacy update","volume":"27","author":"Vij","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib127","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J Clin Oncol"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib128","first-page":"44s","article-title":"PX-171-006: Phase Ib multicenter dose escalation study of carfilzomib (CFZ) plus lenalidomide (LEN) and low-dose dexamethasone (loDex) in relapsed and refractory multiple myeloma (MM): preliminary results","volume":"27","author":"Niesvizky","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib129","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib130","first-page":"455s","article-title":"Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma: a phase I study","volume":"27","author":"Siegel","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib131","doi-asserted-by":"crossref","first-page":"5250","DOI":"10.1158\/1078-0432.CCR-08-2850","article-title":"Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma","volume":"15","author":"Badros","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib132","unstructured":"ClinicalTrials.gov [Web site]. Study of vorinostat (MK0683) an HDAC inhibitor, or placebo in combination with bortezomib in patients with multiple myeloma. Available at: www.clinicaltrials.gov\/ct2\/show\/NCT00773747. Accessed: April 27, 2009."},{"key":"10.3816\/CLML.2010.n.003_bib133","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3852.3852","article-title":"A phase 1b, multicenter, open-label, dose escalation study of oral panobinostat (LBH589) and i.v. bortezomib in patients with relapsed multiple myeloma","volume":"114","author":"San Miguel","year":"2009","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib134","first-page":"444s","article-title":"Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM)","volume":"27","author":"Spencer","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.003_bib135","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1016\/S1557-9190(11)70547-9","article-title":"Panobinostat and Bortezomib Phase I Trial in Multiple Myeloma","volume":"9","author":"Sezer","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib136","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-03-1158","article-title":"Antimyeloma activity of heat shock protein-90 inhibition","volume":"107","author":"Mitsiades","year":"2006","journal-title":"Blood"},{"issue":"15 suppl","key":"10.3816\/CLML.2010.n.003_bib137","first-page":"434s","article-title":"Tanespimycin plus bortezomib in patients with relapsed and refractory multiple myeloma: final results of a phase I\/II study","volume":"27","author":"Richardson","year":"2009","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.003_bib138","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1016\/S1557-9190(11)70553-4","article-title":"Phase I Trial of perifosine, lenalidomide, and dexamethasone in relapsed or refractory myeloma","volume":"9","author":"Jakubowiak","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib139","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1869.1869","article-title":"Perifosine in combination with bortezomib and dexamethasone extends progression-free survival and overall survival in relapsed\/refractory multiple myeloma patients previously treated with bortezomib: updated phase I\/II trial results","volume":"114","author":"Richardson","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib140","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood.V112.11.2773.2773","article-title":"Phase I study of elotuzumab (HuLuc63) in phase I study of elotuzumab (HuLuc63) in relapsed\/refractory multiple myeloma","volume":"112","author":"Zonder","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLML.2010.n.003_bib141","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1158\/1535-7163.MCT-09-0483","article-title":"Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma","volume":"8","author":"van Rhee","year":"2009","journal-title":"Mol Cancer Ther"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.003_bib142","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/S1557-9190(11)70470-X","article-title":"Phase 1b study of elotuzumab (HuLuc63) in combination with lenalidomide in relapsed multiple myeloma","volume":"9","author":"Lonial","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"issue":"suppl 1","key":"10.3816\/CLML.2010.n.003_bib143","first-page":"S45","article-title":"Phase I study of elotuzumab in combination with bortezomib in relapsed multiple myeloma","volume":"9","author":"Jakubowiak","year":"2009","journal-title":"Clin Lymphoma Myeloma"},{"key":"10.3816\/CLML.2010.n.003_bib144","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1158\/1078-0432.CCR-08-2867","article-title":"The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo","volume":"15","author":"Ikeda","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLML.2010.n.003_bib145","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1200\/JCO.2008.18.7252","article-title":"Bendamustine: rebirth of an old drug","volume":"27","author":"Cheson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLML.2010.n.003_bib148","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1080\/10543400902802474","article-title":"Current issues in oncology drug development, with a focus on Phase II trials","volume":"19","author":"Sargent","year":"2009","journal-title":"J Biopharm Stat"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265011700829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:23:14Z","timestamp":1761870194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265011700829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,2]]}},"alternative-id":["S2152265011700829"],"URL":"https:\/\/doi.org\/10.3816\/clml.2010.n.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2010,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Current Status and Future of Multiple Myeloma in the Clinic","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.3816\/CLML.2010.n.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}